|Day Low/High||20.36 / 21.00|
|52 Wk Low/High||11.30 / 27.86|
Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.
The company just beat a bench mark, previously set by Johnson & Johnson.
Jim Cramer is bullish on Xilinx, Arena Pharmaceuticals, Magellan Midstream, Altria and Bank of Montreal.
Cramer says it's the sign of a good market: Investors are finding value in the stocks that were left behind.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
- Primary efficacy analysis successful - significant improvement in pulmonary vascular resistance
Alexion, Arena and Novavax were among the biotech stock movers ahead of the market open on Friday, July 7.
Citi initiated Arena with a 'buy' rating.
Investors considering a purchase of Arena Pharmaceuticals Inc shares, but tentative about paying the going market price of $1.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $1 strike, which has a bid at the time of this writing of 27 cents.
- Lewis Rubin, M.D. and Vallerie McLaughlin, M.D. to Present
Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.
- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -